| abstract |
Inhibitors of ubiquitin-specific protease 19 (USP19) of formula (I) are provided, as well as pharmaceutical compositions comprising the inhibitors, and methods of use thereof. The compounds can be used to treat muscular atrophy, obesity, insulin resistance or type II diabetes or to reduce muscle mass loss. |